IGC Pharma Adds Kerwin Medical Center In Dallas, Texas As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Disease
Benzinga Newsdesk 6 months ago
News
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation studyPOTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study
POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion.